Immunome (NASDAQ:IMNM) Shares Down 3.7%

Immunome, Inc. (NASDAQ:IMNM)’s stock price traded down 3.7% during trading on Thursday . The stock traded as low as $24.31 and last traded at $24.58. 47,250 shares were traded during mid-day trading, a decline of 93% from the average session volume of 681,678 shares. The stock had previously closed at $25.52.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. Leerink Partnrs restated an “outperform” rating on shares of Immunome in a research report on Monday, January 29th. SVB Leerink assumed coverage on shares of Immunome in a research report on Monday, January 29th. They set an “outperform” rating and a $30.00 price objective for the company. Finally, Wedbush upped their price objective on shares of Immunome from $12.00 to $19.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 23rd. Five analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of “Buy” and a consensus target price of $24.50.

Immunome Stock Performance

The stock’s 50 day moving average price is $22.09 and its 200 day moving average price is $13.40. The company has a market capitalization of $1.35 billion, a P/E ratio of -14.10 and a beta of 1.67.

Institutional Investors Weigh In On Immunome

A number of institutional investors have recently modified their holdings of IMNM. TD Asset Management Inc bought a new position in Immunome during the third quarter worth $1,063,000. Acadian Asset Management LLC bought a new position in Immunome during the third quarter worth $414,000. Dorsey Wright & Associates bought a new position in Immunome during the third quarter worth $26,000. Renaissance Technologies LLC bought a new position in Immunome during the first quarter worth $80,000. Finally, Dimensional Fund Advisors LP bought a new position in Immunome during the first quarter worth $77,000. 44.58% of the stock is owned by institutional investors.

About Immunome

Immunome, Inc operates as a biotechnology company that develops targeted cancer therapies. Its portfolio includes immunotherapies, targeted effectors, radioligand therapies, and antibody drug conjugates (ADCs). The company also offers rapid screening of novel antibodies and targets through memory B cell hybridoma technology.